The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Razole 20 mg Gastro-resistant tablets

Rowa Pharmaceuticals LimitedPA0074/073/002

Main Information

Trade NameRazole 20 mg Gastro-resistant tablets
Active SubstancesRabeprazole sodium
Dosage FormGastro-resistant tablet
Licence HolderRowa Pharmaceuticals Limited
Licence NumberPA0074/073/002

Group Information

ATC CodeA02BC Proton pump inhibitors
A02BC04 rabeprazole


License statusAuthorised
Licence Issued11/09/2009
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceAn invented name shall be approved, by variation, prior to marketing of the product. The label shall state that the tablets should be swallowed whole, not chewed or crushed.
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable List CodeIC0015-003-005
Interchangeable List DocumentPDF of Interchangeable List
« Back